Skip to main content Skip to main navigation menu Skip to site footer
Page Header Logo
  • ABOUT THE JOURNAL
    • Focus and scope
    • Editorial Management Process
  • EDITORIAL POLICY
    • Ethical Publication Standards
    • Open Access Policy
    • Anti-plagiarism Policy
    • Copyright
    • Policy for Journal Archiving
    • Claim Policy
  • AUTHORS
    • Guidelines to Authors
    • Sending and Receiving Papers
    • Structure and Content of Articles
    • Article Evaluation Process
    • ORCID
    • coi_disclosure Colombia Médica ICMJE
    • Copyright Transfer Statement Colombia Médica
  • PEER REVIEW
    • Peer Review Process
    • Evaluation Forms
  • EDITORIAL TEAM
    • Editorial team
    • Contact
  • ARTICLES
    • Current
    • Archives
  • COLLECTIONS
Search
  • Register
  • Login
  1. Home /
  2. Archives /
  3. Vol 45 No 3 (2014) /
  4. Editorial

Vaccine against human Papilloma Virus

  • Abstract
  • Author Biography
  • References

Abstract

At present two prophylactic human papilloma virus (HPV) vaccines are commercially available. The Tetravalent vaccine against infection with four VPH types (6, 11, 16, and 18) distributed in the national program in Colombia and the Bivalent vaccine against the VPH types 16 and 18, respectively.  The efficacy and safety of both vaccines has periodically been assessed and they have been declared efficacious and safe by the health authorities of several countries and the Global Advisory Committee on Vaccine Safety ( GACVS ) of the World’s Health Organization (WHO).In its report of March 2014 the GACVS analyzed the evidence of the relationship between the  Human Papillomavirus Vaccine with  >175 million of doses distributed worldwide and autoimmune diseases, particularly Multiple Sclerosis, Aluminum as adjuvant, Vasculitis caused by vaccine DNA fragments and the Complex Regional Pain Syndrome described in Japan.   The Committee ratified the strict vaccine safety control and based on a thorough examination of existing evidence, reaffirmed that the risk-benefit profile remains favorable. The case of the children of Carmen de Bolivar in Colombia has been described by several authors in other countries as "Massive Psychogenic Event", which has absolute no relationship with the vaccine but its high media dissemination resulted into disastrous consequences for the national vaccination program

Authors

  • Julio Cesar Reina Centro Médica Imbanaco
  • Nubia Muñoz Ex-jefe de Epidemiologia en la Agencia Internacional para la Investigación del Cáncer en Lyon, Francia y Profesora Emérita del Instituto de Cancerología de Colombia.

Downloads

Download data is not yet available.

Author Biography


, Ex-jefe de Epidemiologia en la Agencia Internacional para la Investigación del Cáncer en Lyon, Francia y Profesora Emérita del Instituto de Cancerología de Colombia.
Ex-jefe de Epidemiologia en la Agencia Internacional para la Investigación del Cáncer en Lyon, Francia y Profesora Emérita del Instituto de Cancerología de Colombia.

References

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102(5):325–339.

Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human Papillomavirus recombinant vaccine. JAMA. 2009;302:750–757.

Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29:8279–8284.

Arnheim-Dahlström L, Pasternak B, Svaström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906–f5906.

Grimaldi-Bensouda L, Guillemot D, Godeau B, Bénichou J, Lebrun-Frenay C, Papeix C, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014;275(4):398–408.

OMS [30 August 2014];Global Advisory Committee on Vacine Safety. 20140312 a Available from: http://www.who.int/vaccine safety/committee/topics/hpv.

Mitkus RJ, King DB, Hess MA, Forshee RA, Walderhaug MO. Updated Aluminum pharmacokinetics following infant exposures through diet and vaccines. Vaccine. 2011;29:9538–9543.

Buttery JP, Madin S, Crawford NW, Elia S, La Vincente S, Hanieh S, et al. Mass psychogenic response to human papillomavirus vaccination. Med J Aust. 2008;189(5):261–262.

  • PDF (EN)
  • PDF (ES)
  • HTML(En)
  • HTML(Es)
Published
2014-09-30
Submitted
2014-09-24
| 425 |
How to Cite
Reina, J., & Muñoz, N. (2014). Vaccine against human Papilloma Virus. Colombia Médica, 45(3), 94-95. https://doi.org/10.25100/cm.v45i3.1703
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX
Issue
Vol 45 No 3 (2014)
Section
Editorial

The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use

Online ISSN: 1657-9534
Make a Submission

Bibliographics database

Full-text database

Citation Index

Bibliographical information system

Memberships

Licencia Creative Commons
This work is under License Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) .

Indexed

.
0.82
2018CiteScore
 
 
68th percentile
Powered by  Scopus
.
Information
  • For Authors
Universidad del Valle
Universidad del Valle
  • Cali - Colombia
  • © 1994 - 2020
Dirección:
  • Ciudad Universitaria Meléndez
  • Calle 13 # 100-00
  •  
  • Sede San Fernando
  • Calle 4B N° 36-00
PBX:
  • +57 2 3212100
  • Línea gratuita: 018000 22 00 21
  • A.A.25360
Redes Sociales:

2020 Universidad del Valle - Vigilada MinEducación

//Go to www.addthis.com/dashboard to customize your tools